Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04458363 · ClinicalTrials.gov registry record · Early Phase 1
Convalescent Plasma in Pediatric COVID-19
A Early Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT04458363 is a Early Phase 1 study that has completed, run by Emory University. The registered enrollment target is 3 participants.
The verdict
NCT04458363, a Early Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.
Interventions
- BIOLOGICAL Convalescent Plasma (CP)
- DRUG Standard COVID-19 therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-07-04 |
| Est. Completion | 2020-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04458363
The ClinicalTrials.gov registry entry for NCT04458363 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Convalescent Plasma (CP) is the first listed.
NCT04458363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04458363 about?
NCT04458363 is a clinical study titled "Convalescent Plasma in Pediatric COVID-19". COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.
What is the current status of trial NCT04458363?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-07-04. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT04458363?
The interventions under investigation include: Convalescent Plasma (CP) (BIOLOGICAL), Standard COVID-19 therapies (DRUG).
Who is sponsoring clinical trial NCT04458363?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.